0001209191-23-046100.txt : 20230816
0001209191-23-046100.hdr.sgml : 20230816
20230816181007
ACCESSION NUMBER: 0001209191-23-046100
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230814
FILED AS OF DATE: 20230816
DATE AS OF CHANGE: 20230816
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harvey Brian Nicholas
CENTRAL INDEX KEY: 0001519432
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38359
FILM NUMBER: 231179347
MAIL ADDRESS:
STREET 1: C/O RADIUS HEALTH, INC.
STREET 2: 201 BROADWAY, 6TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adicet Bio, Inc.
CENTRAL INDEX KEY: 0001720580
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813305277
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-482-2333
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: resTORbio, Inc.
DATE OF NAME CHANGE: 20171024
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-14
0
0001720580
Adicet Bio, Inc.
ACET
0001519432
Harvey Brian Nicholas
C/O ADICET BIO, INC.
200 BERKELEY STREET, 19TH FLOOR
BOSTON
MA
02116
0
1
0
0
Chief Financial Officer
0
Stock Option (Right to Buy)
13.27
2023-08-14
4
D
0
90000
0.00
D
2031-01-12
Common Stock
90000
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
90000
0.00
A
2031-01-12
Common Stock
90000
90000
D
Stock Option (Right to Buy)
16.82
2023-08-14
4
D
0
28200
0.00
D
2031-02-11
Common Stock
28200
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
28200
0.00
A
2031-02-11
Common Stock
28200
28200
D
Stock Option (Right to Buy)
15.52
2023-08-14
4
D
0
125000
0.00
D
2032-01-06
Common Stock
125000
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
125000
0.00
A
2032-01-06
Common Stock
125000
125000
D
Stock Option (Right to Buy)
9.05
2023-08-14
4
D
0
117200
0.00
D
2033-01-23
Common Stock
117200
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
117200
0.00
A
2033-01-23
Common Stock
117200
117200
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
176308
0.00
A
2033-08-13
Common Stock
176308
176308
D
On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
25% of the shares subject to this option vested and became exercisable on January 13, 2022, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.
25% of the shares subject to this option vested and became exercisable on February 12, 2022, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 7, 2022, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 24, 2023, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Prior to August 14, 2024, no shares shall be vested or exercisable under this option. Effective as of August 14, 2024, the following vesting schedule shall apply: 25% of the shares shall have vested and become exercisable on September 17, 2021, with the remaining 75% vesting in thirty-six (36) equal installments on each monthly anniversary following September 17, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. This option was issued to the Reporting Person because his previously awarded option granted under Nasdaq Listing Rule 5635(c)(4) is not eligible for repricing.
/s/ Nick Harvey
2023-08-16